"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Yields slipped after Powell said that the central bank will continue to act as appropriate to sustain the economic expansion.Bondsread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The president tweeted Friday morning that he was ordering "our great American companies" to "immediately start looking for an alternative to China."Marketsread more
Semiconductor stocks and shares of Apple slid on Friday after President Donald Trump said U.S. companies should "immediately start looking for an alternative" to their...Technologyread more
The two American car companies are among the top exporters of U.S.-produced vehicles to China along with BMW and Daimler/Mercedes-Benz, according to industry data obtained by...Autosread more
Multinationals that rely on the supply chain from China are tumbling after President Donald Trump ordered them find alternatives to their Chinese operations.Marketsread more
Powell repeats his pledge to keep the economic expansion going while acknowledging that tariffs and other factors are causing growth to slow.The Fedread more
These are the stocks posting the largest moves in midday trading.Market Insiderread more
Two former employees of Insys Therapeutics, Jonathan Roper and Fernando Serrano, were arrested on Thursday for allegedly participating in kickback schemes involving doctors who prescribed the company's main drug, Subsys, a pain medication containing fentanyl.
Headlines linking Prince's death to a fentanyl overdose have raised the profile of the opioid; however, CNBC has previously reported on the dangers of these highly addictive drugs and the alleged illegal tactics some pharmaceutical companies have employed to drive sales.
These include allegations against specialty pharmaceutical company Insys, whose market cap is down about a billion dollars since last year. Company officials weren't immediately available to comment on the charges against Roper and Serrano.
According to the Food and Drug Administration, Subsys has only one indication. It's meant for late-stage cancer patients with breakthrough pain, however, Insys has been accused of trying to push the drug far beyond cancer patients by convincing doctors to prescribe it for patients who have migraines or even minor neck or back pain.
According to physicians and experts, Subsys is about 100 times more powerful than morphine.
Roper and Serrano were charged with violating an anti-kickback statute, "in connection with their participation in a scheme to pay doctors thousands of dollars to participate in sham educational programs in order to induce the doctors to prescribe millions of dollars' worth of a fentanyl-based sublingual spray" the company manufactured.
In 2014 alone, these former employees paid one doctor $147,000 and another doctor $112,000 in speaker program fees. These two doctors, during the same time period, were also two of the largest prescribers of the drug in the U.S., according to a press release from Preet Bharara, the U.S. Attorney for the Southern District of New York.
CNBC first reported about these alleged kickback schemes and educational programs, known as speaker fees, in November 2015.
The arrest is part of a bigger question about why so many Americans are addicted to prescription painkillers and what continues to fuel the opioid epidemic, Bharara said in the release.
"As alleged, Roper and Serrano helped feed this devastating surge of opioid addictions by tapping into another age-old addiction, greed," he said.
About 28,000 people died from opioid addiction in 2014, half from painkiller prescriptions, the highest number on record, according to the Centers for Disease Control and Prevention.
Subsys, sprayed under the tongue, is the only drug Insys currently has on the market, and it raked in about $330 million in revenue in 2015 alone.
Insys stock is down 47.5 percent year to date and about 56 percent in the last twelve months.